An Investigation on Bone Mineral Density in Hyperprolactinemia

Hyperprolactinemia patients have been reported to have low Bone Mineral Density (BMD). This study aimed to compare bone mineral density and associated factors in hyperprolactinemia. A total of 35 hyperprolactinemia patients (>100ng/ mL serum prolactin levels) and 10 controls participated in study. Hyperprolactinemia cases were classified into macroprolactinemia and true hyperprolactinemia as determined by Poly-Ethylene Glycol precipitation. Serum levels of Prolactin, Estradiol, Calcium, Phosphate or Alkaline Phosphatase were measured. BMD was measured at lumbar vertebrae, left femur, and left forearm by dual energy x-ray absorptiometry (DXA) scan. The prevalence of osteopenia/osteoporosis was 50% in macroprolactinemia, 70% in true hyperprolactinemia and 60% in controls (statistical differences were insignificant; p = 0.517). Pearson correlation analysis did not find any significant correlation of Prolactin, Estradiol, Calcium, Phosphate or Alkaline Phosphatase with T score or Z score at lumbar spine, femur or forearm (wrist) region in hyperprolactinemia patients and controls. The only significant correlations were found between body mass index (BMI) and prolactin levels (r = 0.473, p = 0.003); and between BMI and total femur T score (r = 0.360, p = 0.015) and Z score (r = 0.362, p = 0.015). Mean BMI was also significantly high (p = 0.029) in hyperprolactinemia patients with normal DXA (28.7±5.3 kg/m2) compared to those with Osteopenia/Osteoporosis (24.7±4.8 kg/m2). There was no significant difference in incidence of osteopenia/ osteoporosis between macroprolactinemia and true hyperprolactinemia patients. The only significant correlation of BMD was found with BMI suggesting high BMI to be a protective factor against osteoporosis in hyperprolactinemia patients.

View article page

Download PDF